Products Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + Meningococcal (group B) multicomponent recombinant adsorbed vaccine + Tdap
Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + Meningococcal (group B) multicomponent recombinant adsorbed vaccine + Tdap Phase 2 Completed ⚡ Active Meningococcal Disease, Meningococcal Meningitis
Jul 1, 2011 → Jul 1, 2012
About Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + Meningococcal (group B) multicomponent recombinant adsorbed vaccine + Tdap Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + Meningococcal (group B) multicomponent recombinant adsorbed vaccine + Tdap is a phase 2 stage product being developed by Novartis for Meningococcal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01367158. Target conditions include Meningococcal Disease, Meningococcal Meningitis.
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT01367158 Phase 2 Completed Jul 1, 2011 Jul 1, 2012 Meningococcal Disease
Product Company Stage Hype Score RotaTeq® + NeisVac-C® Merck Phase 3 Meningococcal C conjugate vaccine Novartis Approved Meningococcal (group B) multicomponent recombinant adsorbed vaccine. + Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV) Novartis Phase 2 Meningococcal ACWY-CRM conjugate vaccine + Meningococcal ACWY-PS polysaccharide vaccine Novartis Phase 3 1a - rMenB+OMV NZ and routine vaccines + 1b - rMenB+OMV NZ and routine vaccines + 2a - Routine and rMenB+OMV NZ vaccines + 2b - rMenB+OMV NZ and routine vaccines + 3a - rMenB+OMV NZ and routine vaccines + 3b - 1 dose of rMenB+OMV NZ plus routine infant vaccinations + 4a- rMenB+OMV NZ and routine vaccines + 4b - rMenB+OMV NZ and routine vaccines Novartis Phase 3 MenACWY-CRM Novartis Pre-clinical Meningococcal C conjugate vaccine Novartis Approved Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine + MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine Novartis Approved rMenB + rMenB+OMV NZ Novartis Phase 2 Typhoid Vi Polysaccharide Vaccine + Yellow Fever Vaccine + Japanese Encephalitis Vaccine + Rabies Vaccine + MenACWY-CRM Vaccine Novartis Phase 3 rMenB+OMV NZ Novartis Phase 3 Meningococcal ACWY Conjugate Vaccine + DTaP-IPV-HBV + Hib + Rotavirus + Pneumococcal 7-valent Conjugate Vaccine + HAV + MMR-V + DTaP Novartis Phase 3 MenACWY-CRM Novartis Phase 3 rMenB + rMenB+OMV Novartis Phase 2 MenC-CRM LIQ + MenC-CRM ROS + MenC-CRM EMV Novartis Phase 2 Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV. + Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV. + Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine. + Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV. Novartis Phase 2 MenABCWY+OMV + MenABCWY+¼OMV + Placebo Novartis Phase 2 Novartis MenACWY-CRM + Saline Placebo Novartis Phase 3 rMenB+OMV NZ + Placebo Novartis Phase 2/3 rMenB + OMV NZ vaccine + rMenB + OMV NZ vaccine + rMenB + OMV NZ vaccine + rMenB + OMV NZ vaccine + Meningococcal C oligosaccharide conjugated vaccine + Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed. + rMenB + OMV NZ vaccine + rMenB + OMV NZ vaccine Novartis Phase 3
Other Products from Novartis